NasdaqCM:ORGS

Stock Analysis Report

Executive Summary

Orgenesis Inc., a biotechnology company, engages in the development, manufacturing, and provision of services in the cell and gene therapy industry.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.

Risks

  • Orgenesis's last earnings update was 188 days ago.
  • Orgenesis is not covered by any analysts.

Similar Companies

Share Price & News

How has Orgenesis's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.6%

NasdaqCM:ORGS

1.5%

US Biotechs

0.9%

US Market


1 Year Return

-33.8%

NasdaqCM:ORGS

-7.3%

US Biotechs

0.3%

US Market

ORGS underperformed the Biotechs industry which returned -8% over the past year.

ORGS underperformed the Market in United States of America which returned -0.5% over the past year.


Share holder returns

ORGSIndustryMarket
7 Day-2.6%1.5%0.9%
30 Day5.1%2.2%-1.9%
90 Day3.7%3.5%1.6%
1 Year-33.8%-33.8%-6.5%-7.3%2.6%0.3%
3 Year-0.4%-0.4%8.9%5.2%41.0%31.8%
5 Year-54.5%-54.5%6.6%1.6%55.2%38.0%

Price Volatility Vs. Market

How volatile is Orgenesis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Orgenesis undervalued based on future cash flows and its price relative to the stock market?

2.39x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Orgenesis to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Orgenesis to establish if it is available at substantial discount.


Price Based on Earnings

Orgenesis is loss making, we can't compare its value to the US Biotechs industry average.

Orgenesis is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Orgenesis, we can't assess if its growth is good value.


Price Based on Value of Assets

Orgenesis is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Orgenesis expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Orgenesis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Orgenesis performed over the past 5 years?

-28.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Orgenesis does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Orgenesis's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Orgenesis's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Orgenesis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Orgenesis has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Orgenesis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Orgenesis's financial position?


Financial Position Analysis

Orgenesis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Orgenesis's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Orgenesis's level of debt (7.1%) compared to net worth is satisfactory (less than 40%).

Orgenesis had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 8.1x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Orgenesis has less than a year of cash runway based on current free cash flow.

Orgenesis has less than a year of cash runway if free cash flow continues to grow at historical rates of 58.1% each year.


Next Steps

Dividend

What is Orgenesis's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Orgenesis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Orgenesis's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Orgenesis has not reported any payouts.

Unable to verify if Orgenesis's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Orgenesis has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Orgenesis's salary, the management and board of directors tenure and is there insider trading?

5.0yrs

Average management tenure


CEO

Vered Caplan (50yo)

5.7yrs

Tenure

US$1,975,590

Compensation

Ms. Vered Caplan, M.Sc., has been the President and Chief Executive Officer of Orgenesis Inc. since August 14, 2014. Ms. Caplan is the Sole Owner of PBD Ltd. Ms. Caplan has been the Chief Executive Officer ...


CEO Compensation Analysis

Vered's remuneration is higher than average for companies of similar size in United States of America.

Vered's compensation has increased whilst company is loss making.


Management Age and Tenure

5.0yrs

Average Tenure

49.5yo

Average Age

The average tenure for the Orgenesis management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

6.2yrs

Average Tenure

54yo

Average Age

The tenure for the Orgenesis board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$1,50008 Jan 19
Hugues Bultot
EntityIndividual
Shares300
Max PriceUS$5.00

Ownership Breakdown


Management Team

  • Neil Reithinger (49yo)

    CFO, Secretary & Treasurer

    • Tenure: 5.0yrs
    • Compensation: US$406.04k
  • Vered Caplan (50yo)

    Chairman

    • Tenure: 5.7yrs
    • Compensation: US$1.98m
  • Sarah Ferber (65yo)

    Founder & Chief Scientific Officer

    • Tenure: 0.0yrs
    • Compensation: US$268.78k
  • Denis Bedoret (38yo)

    Managing Director of MaSTherCell

    • Tenure: 0.9yrs
    • Compensation: US$288.60k

Board Members

  • Guy Yachin (51yo)

    Director

    • Tenure: 7.3yrs
    • Compensation: US$230.77k
  • Jay Skyler (72yo)

    Scientific Advisor

    • Tenure: 6.3yrs
    • Compensation: US$9.41k
  • David Sidransky (59yo)

    Director

    • Tenure: 6.1yrs
    • Compensation: US$119.73k
  • Itamar Raz (71yo)

    • Tenure: 4.4yrs
  • Vered Caplan (50yo)

    Chairman

    • Tenure: 5.7yrs
    • Compensation: US$1.98m
  • Yaron Adler (48yo)

    Director

    • Tenure: 7.3yrs
    • Compensation: US$90.16k
  • Zan Fleming

    Scientific Advisor

    • Tenure: 7.3yrs
    • Compensation: US$67.20k
  • Camillo Ricordi

    Scientific Advisor

    • Tenure: 6.8yrs
    • Compensation: US$8.96k
  • Ashish Nanda (54yo)

    Director

    • Tenure: 2.5yrs
    • Compensation: US$17.28k
  • Lorenzo Piemonti

    Member Scientific Advisory Board

    • Tenure: 1.3yrs

Company Information

Orgenesis Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Orgenesis Inc.
  • Ticker: ORGS
  • Exchange: NasdaqCM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$73.280m
  • Shares outstanding: 16.14m
  • Website: https://www.orgenesis.com

Number of Employees


Location

  • Orgenesis Inc.
  • 20271 Goldenrod Lane
  • Germantown
  • Maryland
  • 20876
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ORGSNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDOct 2009

Biography

Orgenesis Inc., a biotechnology company, engages in the development, manufacturing, and provision of services in the cell and gene therapy industry. The CDMO segment specializes in therapy development serv ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/20 00:17
End of Day Share Price2019/08/19 00:00
Earnings2018/11/30
Annual Earnings2018/11/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.